Advances in drug design with RXR modulators

Bibliography

• Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim Biophys Acta (BBA) Mol Cell Biol Lipids 2012;1821:21-56
   PubMed Web of Science ®Google Scholar
• de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a Case Study. Nat Rev Drug Disc 2007;6:811-20
   PubMed Web of Science ®Google Scholar
• Pérez E, Bourguet W, Gronemeyer H, de Lera AR. Modulation of RXR function through ligand design. Biochim Biophysica Acta (BBA) Mol Cell Biol Lipids 2012;1821:57-69
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metabol 2010;21:676-83
   PubMed Web of Science ®Google Scholar
• Álvarez S, Bourguet W, Gronemeyer H, de Lera AR. Retinoic acid receptor modulators: a perspective on recent advances and promises. Expert Opin Ther Patents 2011;21:55-63
   PubMed Web of Science ®Google Scholar
• Bourguet W, Ruff M, Chambon P, Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 1995;375:377-82
   PubMed Web of Science ®Google Scholar
• Egea PF, Mitschler A, Rochel N, Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid. EMBO J 2000;19:2592-601
   PubMed Web of Science ®Google Scholar
• Klaholz BP, Renaud J-P, Mitschler A, Conformational adaptation of agonists to the human nuclear receptor RARγ. Nat Struct Mol Biol 1998;5:199-202
   Web of Science ®Google Scholar
• Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990;345:224-9
   PubMed Web of Science ®Google Scholar
• Ijpenberg A, Tan NS, Gelman L, In vivo activation of PPAR target genes by RXR homodimers. EMBO J 2004;23:2083-91
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen L, Chen J, Structural basis for retinoic X receptor repression on the tetramer. J Biol Chem 2011;286:24593-8
   PubMed Web of Science ®Google Scholar
• Bourguet W, Vivat V, Wurtz J-M, Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000;5:289-98
   PubMed Web of Science ®Google Scholar
• Pogenberg V, Guichou J-F, Vivat-Hannah V, Characterization of the Interaction Between RAR/RXR Heterodimers and Transcriptional Coactivators Through Structural and Fluorescence Anisotropy Studies. J Biol Chem 2005;280:1625-33
   PubMed Web of Science ®Google Scholar
• Sato Y, Ramalanjaona N, Huet T, The "Phantom Effect" of the rexinoid LG100754: structural and functional insights. PLoS ONE 2010;5:e15119
   PubMed Web of Science ®Google Scholar
• Haffner CD, Lenhard JM, Miller AB, Structure-based design of potent retinoid X receptor α agonists. J Med Chem 2004;47:2010-29
   PubMed Web of Science ®Google Scholar
• Gampe RT, Montana VG, Lambert MH, Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 2000;5:545-55
   PubMed Web of Science ®Google Scholar
• Svensson S, Ostberg T, Jacobsson M, Crystal structure of the heterodimeric complex of LXRα and RXRβ ligand-binding domains in a fully agonistic conformation. EMBO J 2003;22:4625-33
   PubMed Web of Science ®Google Scholar
• Suino K, Peng L, Reynolds R, The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 2004;16:893-905
   PubMed Web of Science ®Google Scholar
• Osz J, Brélivet Y, Peluso-Iltis C, Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors. Proc Natl Acad Sci USA 2012;109:E588-E94
   PubMed Web of Science ®Google Scholar
• Rochel N, Ciesielski F, Godet J, Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat Struct Mol Biol 2011;18:564-70
   PubMed Web of Science ®Google Scholar
• Chandra V, Huang P, Hamuro Y, Structure of the intact PPARγ-RXRα nuclear receptor complex on DNA. Nature 2008;456:350-56.
   PubMed Web of Science ®Google Scholar
• Germain P, Iyer J, Zechel C, Gronemeyer H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 2002;415:187-92
   PubMed Web of Science ®Google Scholar
• le Maire A, Teyssier C, Erb C, A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat Struct Mol Biol 2010;17:801-7
   PubMed Web of Science ®Google Scholar
• Putcha B-DK, Wright E, Brunzelle JS, Fernandez EJ. Structural basis for negative cooperativity within agonist-bound TR:RXR heterodimers. Proc Natl Acad Sci USA 2012;109:6084-7
   PubMed Web of Science ®Google Scholar
• Egea PF, Mitschler A, Moras D. Molecular recognition of agonist ligands by RXRs. Mol Endocrinol 2002;16:987-97
   PubMed Web of Science ®Google Scholar
• Lu J, Dawson MI, Hu QY, The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain. Magn Reson Chem 2009;47:1071-80
   PubMed Web of Science ®Google Scholar
• Nahoum V, Pérez E, Germain P, Modulators of the structural dynamics of RXR to reveal receptor function. Proc Natl Acad Sci USA 2007;104:17323-8
   PubMed Web of Science ®Google Scholar
• Pérez-Santín E, Germain P, Quillard F, Modulating retinoid X receptor with a series of (E)-3-[4-Hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. J Med Chem 2009;52:3150-8
   PubMed Web of Science ®Google Scholar
• Wolf G. Is 9-Cis-Retinoic acid the endogenous ligand for the retinoic acid-X receptor? Nutr Rev 2006;64:532-8
   PubMed Web of Science ®Google Scholar
• Calléja C, Messaddeq N, Chapellier B, Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev 2006;20:1525-38
   PubMed Web of Science ®Google Scholar
• Wallén-Mackenzie Ö, Mata de Urquiza A, Petersson S, Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev 2003;17:3036-47
   PubMed Web of Science ®Google Scholar
• Moise AR, Alvarez S, Domínguez M, Activation of retinoic acid receptors by dihydroretinoids. Mol Pharmacol 2009;76:1228-37
   PubMed Web of Science ®Google Scholar
• Ziouzenkova O, Orasanu G, Sharlach M, Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med 2007;13:695-702
   PubMed Web of Science ®Google Scholar
• de Urquiza AM, Liu S, Sjöberg M, Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse. Brain Sci 2000;290:2140-4
   Google Scholar
• Harmon MA, Boehm MF, Heyman RA, Mangelsdorf DJ. Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci USA 1995;92:6157-60
   PubMed Web of Science ®Google Scholar
• Kitareewan S, Burka L, Tomer B, Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Cell Biol 1996;7:1153-66
   Google Scholar
• LeMotte PK, Keidek S, Apfel CM. Phytanic acis is a retinoid X receptor ligand. Eur J Biochem 1996;236:328-33
   PubMedGoogle Scholar
• Zomer AWM, van der Burg B, Jansen GA, Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor γ. J Lipid Res 2000;41:1801-7
   PubMed Web of Science ®Google Scholar
• Álvarez S, Pazos-Randulfe Y, Khanwalkar H, New retinoid chemotypes: 9-cis-Retinoic acid analogs with hydrophobic rings derived from terpenes as selective RAR agonists. Bioorg Med Chem 2008;16:9719-28
   PubMed Web of Science ®Google Scholar
• Okitsu T, Sato K, Iwatsuka K, Replacement of the hydrophobic part of 9-cis-retinoic acid with cyclic terpenoid moiety results in RXR-selective agonistic activity. Bioorg Med Chem 2011;19:2939-49
   PubMed Web of Science ®Google Scholar
• Apfel CM, Kamber M, Klaus M, Enhancement of HL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor. J Biol Chem 1995;270:30765-72
   PubMed Web of Science ®Google Scholar
• Dawson MI. Synthetic retinoids and their nuclear receptors. Curr Med Chem Anti Cancer Agents 2004;4:199-230
   PubMedGoogle Scholar
• Balasubramanian S, Chandraratna RAS, Eckert RL. Supression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. Carcinogenesis 2004;25:1377-85
   PubMed Web of Science ®Google Scholar
• Liby K, Royce DB, Risingsong R, A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res 2007;13:6237-43
   PubMed Web of Science ®Google Scholar
• Muccio DD, Brouillette WJ, Breitman TR, Conformationally defined retinoid acid analogues. 4. Potential new agents for acute promielocytic and juvenile myelomonocytic leukemias. J Med Chem 1998;41:1679-87
   PubMed Web of Science ®Google Scholar
• Kolesar JM, Hoel R, Pomplun M, A Pilot, First-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Cancer Prev Res 2010;3:1565-70
   PubMed Web of Science ®Google Scholar
• Kapetanovic IM, Horn TL, Johnson WD, Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention. Int J Toxicol 2010;29:157-64
   PubMed Web of Science ®Google Scholar
• Farmer LJ, Zhi L, Jeong S, Retinoic acid receptor ligands based on the 6-Cyclopropyl-2,4-hexadienoic acid. Bioorg Med Chem Lett 2003;13:261-4
   PubMed Web of Science ®Google Scholar
• Michellys PY, Ardecky RA, Chen J-H, Design, synthesis and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic Acids. J Med Chem 2003;46:4087-103
   PubMed Web of Science ®Google Scholar
• Leibowitz MD, Ardecky RJ, Boehm MF, Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 2006;147:1044-53
   PubMed Web of Science ®Google Scholar
• Michellys PY, Ardecky RA, Chen J-H, Novel (2E,4E,6Z)-7-(2-Alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. J Med Chem 2003;46:2683-96
   PubMed Web of Science ®Google Scholar
• Gernert DL, Ajamie R, Ardecky RA, Design and synthesis of fluorinated RXR modulators. Bioorg Med Chem Lett 2003;13:3191-5
   PubMed Web of Science ®Google Scholar
• Michellys PY, D’Arrigo J, Grese TA, Design, synthesis and structure-activity relationship of novel RXR-selective modulators. Bioorg Med Chem Lett 2004;14:1593-8
   PubMed Web of Science ®Google Scholar
• Canan Koch SS, Dardashti LJ, Hebert JJ, Identification of the first retinoid X receptor homodimer antagonist. J Med Chem 1996;39:3229-34
   PubMed Web of Science ®Google Scholar
• Schulman IG, Li C, Schwabe JW, Evans RM. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev 1997;11:299-308
   PubMed Web of Science ®Google Scholar
• Boehm MF, Zhang L, Zhi L, Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995;38:3146-55
   PubMed Web of Science ®Google Scholar
• Sherman SI, Gopal J, Haugen BR, Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075-9
   PubMed Web of Science ®Google Scholar
• Wagner CE, Jurutka PW, Marshall PA, Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (Bexarotene). J Med Chem 2009;52:5950-66
   PubMed Web of Science ®Google Scholar
• Smit JWA, Stokkel MPM, Pereira AM, Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metabol 2007;92:2496-9
   PubMed Web of Science ®Google Scholar
• Heald P. The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clin Lymphoma 2000;1:S45-9
   PubMedGoogle Scholar
• Blumenschein GR, Khuri FR, von Pawel J, Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 2008;26:1879-85
   PubMed Web of Science ®Google Scholar
• Wildi JD, Baggstrom MQ, Suresh R, Phase I study of docetaxel and bexarotene. Chemotherapy 2008;54:125-30
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Glaspy J, Baidas S, Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003;21:999-1006
   PubMed Web of Science ®Google Scholar
• Ramlau R, Zatloukal P, Jassem J, Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 2008;26:1886-92
   PubMed Web of Science ®Google Scholar
• Daiss JO, Burschka C, Mills JS, Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disila-analogue of the RXR-selective retinoid agonist bexarotene. Organometallics 2005;24:3192-9
   Web of Science ®Google Scholar
• Lippert WP, Christian B, Kathrin G, Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem 2009;4:1143-52
   PubMed Web of Science ®Google Scholar
• Bauer JB, Lippert WP, Dörrich S, Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells. ChemMedChem 2011;6:1509-17
   PubMed Web of Science ®Google Scholar
• Faul MM, Ratz AM, Sullivan KA, Synthesis of novel retinoid X receptor-selective retinoids. J Org Chem 2001;66:5772-82
   PubMed Web of Science ®Google Scholar
• Canan-Koch SS, Dardashti LJ, Cesario RM, Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells. J Med Chem 1999;42:742-50
   PubMed Web of Science ®Google Scholar
• Umemiya H, Fukasawa H, Ebisawa M, Regulation of retinoidal actions by diazepinylbenzoic acids. retinoid synergists activate the RXR-RAR heterodimers. J Med Chem 1997;40:4222-34
   PubMed Web of Science ®Google Scholar
• Ebisawa M, Umemiya H, Ohta K, Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem Pharm Bull 1999;47:1778-86
   PubMed Web of Science ®Google Scholar
• Sakaki J, Kishida M, Konishi K, Synthesis and structure-activity relationship of novel RXR antagonists: orally active anti-diabetic and anti-obesity agents. Bioorg Med Chem Lett 2007;17:4804-7
   PubMed Web of Science ®Google Scholar
• Sakaki J, Konishi K, Kishida M, Synthesis and structure-activity relationship of RXR antagonists based on the diazepinylbenzoic acid structure. Bioorg Med Chem Lett 2007;17:4808-11
   PubMed Web of Science ®Google Scholar
• Ohta K, Kawachi E, Fukasawa H, Diphenylamine-based retinoid antagonists: regulation of RAR and RXR function depending on the N-substituent. Bioorg Med Chem 2011;19:2501-7
   PubMed Web of Science ®Google Scholar
• Ohta K, Tsuji M, Kawachi E, Potent retinoid synergists with a diphenylamine skeleton. Biol Pharm Bull 1998;21:544-6
   PubMed Web of Science ®Google Scholar
• Ohta K, Iijima T, Kawachi E, Novel retinoid X receptor (RXR) antagonists having a dicarba-closo-dodecaborane as a hydrophobic moiety. Bioorg Med Chem Lett 2004;14:5913-18
   PubMed Web of Science ®Google Scholar
• Takahashi B, Ohta K, Kawachi E, Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimers. J Med Chem 2002;45:3327-9
   PubMed Web of Science ®Google Scholar
• Ohsawa F. Morishita K-i, Yamada S, Makishima M, et al. Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers. ACS Med Chem Lett 2010;1:521-5
   PubMed Web of Science ®Google Scholar
• Nakayama M, Yamada S, Ohsawa F, Discovery of a potent retinoid X receptor antagonist structurally closely related to RXR agonist NEt-3IB. ACS Med Chem Lett 2011;2:896-900
   PubMed Web of Science ®Google Scholar
• Fujii S, Ohsawa F, Yamada S, Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation. Bioorg Med Chem 2010;20:5139-42
   Web of Science ®Google Scholar
• Bernardon J-M. Preparation of bicyclic aromatic compounds and their use in cosmetic or dermatological compositions. PCT Int. Appl. WO9733881; 1997
   Google Scholar
• García J, Khanwalkar H, Pereira R, Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors. ChemBioChem 2009;10:1252-9
   PubMed Web of Science ®Google Scholar
• Pérez-Rodríguez S, Ortiz MA, Pereira R, Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles. Eur J Med Chem 2009;44:2434-46
   PubMed Web of Science ®Google Scholar
• Lagu B, Pio B, Lebedev R, RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia. Bioorg Med Chem Lett 2007;17:3497-503
   PubMed Web of Science ®Google Scholar
• Lagu B, Lebedev R, Pio B, Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia. Bioorg Med Chem Lett 2007;17:3491-6
   PubMed Web of Science ®Google Scholar
• Kotani H, Tanabe H, Mizukami H, Identification of a Naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J Nat Prod 2010;73:1332-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhou R, Li L, Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. J Biol Chem 2011;286:1868-75
   PubMed Web of Science ®Google Scholar
• Zhang H, Li L, Chen L, Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode. J Mol Biol 2011;407:13-20
   PubMed Web of Science ®Google Scholar
• Ziouzenkova O, Orasanu G, Sukhova G, Asymmetric cleavage of β-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol 2007;21:77-88
   PubMed Web of Science ®Google Scholar
• Eroglu A, Hruszkewycz DP, Curley RW Jr, Harrison EH. The eccentric cleavage product of β-carotene, β-apo-13-carotenone, functions as an antagonist of RXRα. Arch Biochem Biophys 2010;504:11-16
   PubMed Web of Science ®Google Scholar
• Kolluri SK, Corr M, James SY, The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 2005;102:2525-30
   PubMed Web of Science ®Google Scholar
• Zhou H, Liu W, Su Y, NSAID sulindac and its analog bind RXR ± and nhibit RXR ±-dependent AKT signaling. Cancer Cell 2010;17:560-73
   PubMed Web of Science ®Google Scholar
• Venhorst J, Núñez S, Terpstra JW, Kruse CG. Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. J Med Chem 2008;51:3222-9
   PubMed Web of Science ®Google Scholar
• Dawson MI, Ye M, Cao X, Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor γ Ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene. ChemMedChem 2009;4:1106-19
   PubMed Web of Science ®Google Scholar
• le Maire A, Grimaldi M, Roecklin D, Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep 2009;10:367-73
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, The pharmacology and classification of the nuclear receptor superfamily. RETINOID X RECEPTORS (RXRs). Pharmacol Rev 2006;58:760-72
   PubMed Web of Science ®Google Scholar
• Takamatsu K, Takano A, Yakushiji N, The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRα/β-dual agonist). ChemMedChem 2008;3:780-7
   PubMed Web of Science ®Google Scholar
• Takamatsu K, Takano A, Yakushiji N, Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRα-preferential agonist possessing a sulfonamide moiety. ChemMedChem 2008;3:454-60
   PubMed Web of Science ®Google Scholar
• Morishita K, Yakushiji N, Ohsawa F, Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity. Bioorg Med Chem Lett 2009;19:1001-3
   PubMed Web of Science ®Google Scholar
• Kakuta H, Yakushiji N, Shinozaki R, RXR partial agonist CBt-PMN exerts therapeutic effects on type 2 diabetes without the side effects of RXR full agonists. ACS Med Chem Lett 2012;3:427-32
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Waki H, Kamon J, Inhibition of RXR and PPARg ameliorates diet-induced obesity and type 2 diabetes. J Clin Inv 2001;108:1001-13
   PubMed Web of Science ®Google Scholar
• Altucci L, Leibowitz MD, Ogilvie KM, RAR and RXR modulation in cancer and Metabolic disease. Nat Rev Drug Disc 2007;6:793-810
   PubMed Web of Science ®Google Scholar
• Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69
   PubMed Web of Science ®Google Scholar
• Cramer PE, Cirrito JR, Wesson DW, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-6
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Davies PJA, Crombie DL, Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386:407-10
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38
   PubMed Web of Science ®Google Scholar